{"database": "lobbying", "table": "lobbying_activities", "rows": [[834262, "4a3a28e4-bd91-4681-b34b-71e59ad2806b", "Q3", "TARPLIN STRATEGIES LLC", 40032282, "GENENTECH, INC.", 2009, "third_quarter", "PHA", "H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics.\nH.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics.\nH.R. 3200, America's Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period.\nS. 1679, the Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program.\nSenate Finance Committee Chairman's Mark, America's Healthy Future Act - Medicare and Medicaid reimbursement issues, possible taxes and fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit.\nS. 1232, the Pharmaceutical Market Access and Drug Safety Act, importation of prescription drugs.", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 75000, null, 0, 0, "2009-10-18T15:40:26-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["834262"], "units": {}, "query_ms": 0.7255839882418513, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}